Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

  • Selected Papers of the 5th Congress of the European Society of Urological Oncology and Endocrinology, August 18–20, 1986, Edinburgh, UK
  • Published:

Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions

  • 27 Accesses

  • 10 Citations


Human prostatic tissue and expressed prostatic secretions (EPS) efrom patients with benign prostatic hyperplasia (BPH) and prostate cancer were incubated with (1 β 3H) androstenedione. The extent of aromatization was determined by measuring the transfer of 3H from the 1 β position into water. The amount of 3H2O recovered corresponds to the estrogens formed. Tissue from 5 patients with BPH yielded 2.13 (±1.05) pmol/mg protein/h while the EPS from the same patients yielded 727 fmol/mg protein/h. In patients with prostate cancer the mean formation of estrogens was 388 fmol/mg protein/h (±75). 4-hydroxyandrostenedione, an aromatase inhibitor, successfully inhibited aromatization in BPH and prostate cancer 53–98%.

This is a preview of subscription content, log in to check access.


  1. 1.

    Anderson RU, Fair WR (1976) Physical and chemical determinations of prostatic secretion in benign hyperplasia, prostatitis, and adenocarcinoma. Invest Urol 14:137–139

  2. 2.

    Bouton MM, Porin C, Grandadan JA (1981) Estrogen regulation of rat prostate androgen receptor. J Steroid Biochem 15:403–408

  3. 3.

    Cooms RC, Dowsett M, Goss P, Gazet JC, Brodie A (1984) 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1237–1239

  4. 4.

    Fishman J, Goto J (1981) Mechanisms of estrogen biosynthesis. J Biol Chem 256:4466–4471

  5. 5.

    Grayhack JT, Lee C, Oliver L, Schaeffer AJ, Wendel EF (1980) Bichemical profiles of prostatic fluid from normal and diseased prostate glands. Prostate 1:227–237

  6. 6.

    Harper ME, Pierrepoint CG, Griffiths K (1984) Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20:477–482

  7. 7.

    Kozak I, Bartsch W, Krieg M, Voigt KD (1982) Nuclei of stroma: site of highest estrogen concentration in human prostatic hyperplasia. Prostate 3:433–438

  8. 8.

    Krieg M, Bartsch W, Thompson M, Voigt KD (1983) Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 19:155–161

  9. 9.

    Lowry OH, Rosenburgh NJ, Farr LA, Randall RJ (1951) Protein measurement with the folin penol reagent. J Biol Chem 193:265–269

  10. 10.

    Meikle AW, Stanish WM (1982) Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 54:1104–1107

  11. 11.

    Miyairi S, Fishman J (1985) Radiometric analysis of oxidative reactions in aromatization by placental microsomes. J Biol Chem 260:320–325

  12. 12.

    Rose DR, Laakso K, Sotarauta M, Wynder EL (1984) Hormone levels in prostatic fluid from healthy finns and prostate cancer patients. Eur J Cancer Clin Oncol 10:1317–1319

  13. 13.

    Schweikert HU (1979) conversion of androstenedione to estrone in human fibroblasts cultured from prostate, genitals and nongenital skin. Hormone Metab Res 11:635–640

  14. 14.

    Stone NN, Fair WR, Fishman J (1986) Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Prostate 9:311–318

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stone, N.N., Laudone, V.P., Fair, W.R. et al. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol. Res. 15, 165–167 (1987).

Download citation

Key words

  • Aromatization
  • BPH
  • Prostate cancer
  • Prostatic secretions